The clinical significance of MBP (68-86) in neurological disorders

I. Introduction

Myelin Basic Protein (MBP) is a protein specific to the central nervous system (CNS), localized on the cytoplasmic surface of the myelin sheath and tightly bound to myelin lipids, playing a key role in maintaining the structural stability and functional integrity of the myelin sheath. Changes in MBP levels can reflect the severity of oligodendrocyte myelin damage in the white matter, serving as an objective biochemical marker for CNS damage and acute demyelination. MBP (68-86), as a core antigenic epitope fragment of the MBP protein, holds significant value in autoimmune response research. This article systematically elaborates on the biological characteristics and clinical significance of MBP and GFAP, with a focus on the application of MBP (68-86) in related disease studies.

II. Biological Characteristics of MBP

MBP is a protein specific to the CNS, located on the cytoplasmic surface of the myelin sheath and tightly bound to myelin lipids, maintaining the structural and functional stability of the myelin sheath and playing an insulating and rapid conduction role in nerve fibers. When the CNS is damaged, the blood-brain barrier function is disrupted, leading to changes in permeability and an increase in serum MBP levels. Measuring MBP concentrations in serum and cerebrospinal fluid can serve as a direct quantitative indicator to assess the severity of neural damage, the extent of injury, disease progression, and prognosis, providing significant guidance for treatment.

MBP (68-86) is a key antigenic epitope fragment within the MBP molecule, comprising amino acid residues 68 to 86. This fragment has been confirmed as an important pathogenic antigenic determinant in experimental autoimmune encephalomyelitis (EAE) animal models, capable of inducing T-cell responses and antibody production, making it a valuable tool for studying MBP-related autoimmune mechanisms.

III. Biological Characteristics of GFAP

Glial Fibrillary Acidic Protein (GFAP) is an intermediate filament protein specific to astrocytes, forming a crucial component of the cytoskeleton and serving as a specific marker for astrocytes. GFAP astrocytopathy is a neurological autoimmune disease first defined in 2016, characterized by the presence of immunoglobulin G autoantibodies targeting GFAP in patients. The disease presents with diverse clinical manifestations, most commonly meningoencephalitis, including encephalopathy, seizures, psychiatric symptoms, tremors, and potential involvement of any CNS region from the optic nerve to the spinal cord.

Following traumatic brain injury, GFAP is released from damaged astrocytes and enters the peripheral blood through the compromised blood-brain barrier, leading to a significant increase in serum GFAP concentrations. Studies indicate that GFAP levels can reflect the extent and severity of neural cell damage, with more severe injuries resulting in higher GFAP release. Thus, GFAP serves as a serological marker for evaluating the prognosis of traumatic brain injury.

IV. Clinical Significance of MBP

(1) Acute Traumatic Brain Injury

Acute traumatic brain injury has high mortality and disability rates, with severe traumatic brain injury being a critical focus of treatment. MBP can serve as a sensitive and specific marker for brain trauma. Serum MBP concentrations after severe brain trauma are closely related to the severity of primary brain injury and intracranial lesions reflected by CT. Animal experiments show that MBP levels in the hypothalamus and hippocampal tissues increase to varying degrees after severe trauma, with MBP levels in body fluids influenced by the injury site. Superficial cortical and periventricular lesions are more likely to release MBP into cerebrospinal fluid and blood compared to deep cortical injuries. Clinical studies confirm that higher MBP levels in brain trauma patients correlate with poorer prognosis.

(2) Acute Cerebral Infarction

After cerebral infarction, myelin in the ischemic core undergoes necrosis, participating in the inflammatory response around the infarction area. Larger infarct sizes and more severe conditions correlate with higher MBP concentrations, reflecting the extent of secondary brain damage.

(3) Acute Cerebral Hemorrhage

Serum MBP concentrations after cerebral hemorrhage can reflect the extent of secondary brain damage, providing a reference for assessing the condition.

(4) Brain Tumors

The volume of peritumoral brain edema is positively correlated with MBP levels in serum and cerebrospinal fluid, with patients exhibiting increased intracranial pressure showing higher MBP levels than those without. Measuring MBP levels aids in distinguishing benign from malignant tumors and estimating the extent of CNS damage.

(5) Multiple Sclerosis

Multiple sclerosis (MS) is an autoimmune disease characterized by CNS inflammatory demyelination. Serum and cerebrospinal fluid MBP are specific biochemical markers reflecting CNS demyelination, with their levels indicating the extent and severity of damage. Healthy individuals do not exhibit anti-MBP antibodies in peripheral blood, whereas MS patients do. Measuring MBP levels provides valuable reference for MS diagnosis and treatment monitoring. MBP (68-86), as a core antigenic epitope, is widely used in MS autoimmune mechanism research to detect antigen-specific T-cell responses and antibody reactions.

V. Summary

MBP and GFAP, as CNS-specific proteins, hold significant value in the diagnosis and assessment of neurological diseases. MBP (68-86), as a key antigenic epitope fragment, provides an important tool for studying MBP-related autoimmune mechanisms. Measuring MBP and GFAP levels aids in determining the extent of neural damage, guiding treatment decisions, and evaluating prognosis, with broad application prospects in traumatic brain injury, cerebrovascular diseases, demyelinating diseases, and autoimmune encephalitis.

VI. Which Manufacturers Provide MBP (68-86)?

Nanjing UA-Bio Technology Co., Ltd. (UA-Bio) has independently developed "MBP (68-86)", a high-quality peptide reagent specifically designed for studying the immunogenicity and autoimmune responses of myelin basic protein (MBP). This peptide covers amino acid residues 68-86 of human MBP protein (MBP 68-86, also known as MBP 68-86 peptide), containing well-defined T-cell and B-cell antigenic epitopes. It provides a stable and reliable standardized tool for research on the mechanisms of demyelinating diseases such as multiple sclerosis, autoimmune model construction, and immune intervention evaluation.

Nanjing UA-Bio Technology Co., Ltd. is committed to providing cutting-edge, high-quality core reagents and tools for immunology, cell therapy, and innovative drug development. For detailed technical parameters, validation data, or specific application inquiries regarding "MBP (68-86)" (Product No.: UA080404), please feel free to contact us.